Capricor Therapeutics Stock Performance
| CAPR Stock | USD 23.20 0.97 4.01% |
Capricor Therapeutics holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 3.56, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Capricor Therapeutics will likely underperform. Use Capricor Therapeutics semi variance, and the relationship between the treynor ratio and daily balance of power , to analyze future returns on Capricor Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Capricor Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Capricor Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 14.7 M | |
| Total Cashflows From Investing Activities | -116.2 M |
Capricor Therapeutics Relative Risk vs. Return Landscape
If you would invest 618.00 in Capricor Therapeutics on October 27, 2025 and sell it today you would earn a total of 1,702 from holding Capricor Therapeutics or generate 275.4% return on investment over 90 days. Capricor Therapeutics is currently generating 5.8209% in daily expected returns and assumes 47.5812% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Capricor, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Capricor Therapeutics Target Price Odds to finish over Current Price
The tendency of Capricor Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 23.20 | 90 days | 23.20 | about 30.42 |
Based on a normal probability distribution, the odds of Capricor Therapeutics to move above the current price in 90 days from now is about 30.42 (This Capricor Therapeutics probability density function shows the probability of Capricor Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.56 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Capricor Therapeutics will likely underperform. In addition to that Capricor Therapeutics has an alpha of 5.5676, implying that it can generate a 5.57 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Capricor Therapeutics Price Density |
| Price |
Predictive Modules for Capricor Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Capricor Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Capricor Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Capricor Therapeutics is not an exception. The market had few large corrections towards the Capricor Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Capricor Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Capricor Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 5.57 | |
β | Beta against Dow Jones | 3.56 | |
σ | Overall volatility | 10.40 | |
Ir | Information ratio | 0.12 |
Capricor Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Capricor Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Capricor Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Capricor Therapeutics is way too risky over 90 days horizon | |
| Capricor Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 22.27 M. Net Loss for the year was (40.47 M) with loss before overhead, payroll, taxes, and interest of (64.75 M). | |
| Capricor Therapeutics currently holds about 51.42 M in cash with (40 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11. | |
| Roughly 17.0% of the company shares are held by company insiders |
Capricor Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Capricor Stock often depends not only on the future outlook of the current and potential Capricor Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Capricor Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 35.2 M | |
| Cash And Short Term Investments | 151.5 M |
Capricor Therapeutics Fundamentals Growth
Capricor Stock prices reflect investors' perceptions of the future prospects and financial health of Capricor Therapeutics, and Capricor Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Capricor Stock performance.
| Return On Equity | -1.08 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (7.79) % | |||
| Current Valuation | 1.18 B | |||
| Shares Outstanding | 54.4 M | |||
| Price To Earning | 42.39 X | |||
| Price To Book | 15.05 X | |||
| Price To Sales | 113.39 X | |||
| Revenue | 22.27 M | |||
| EBITDA | (41.14 M) | |||
| Cash And Equivalents | 51.42 M | |||
| Cash Per Share | 2.11 X | |||
| Total Debt | 1.45 M | |||
| Debt To Equity | 0.15 % | |||
| Book Value Per Share | 1.83 X | |||
| Cash Flow From Operations | (40 M) | |||
| Earnings Per Share | (1.75) X | |||
| Total Asset | 170.48 M | |||
| Retained Earnings | (199.83 M) | |||
| Current Asset | 22.4 M | |||
| Current Liabilities | 6.67 M | |||
About Capricor Therapeutics Performance
Assessing Capricor Therapeutics' fundamental ratios provides investors with valuable insights into Capricor Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Capricor Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. The company was founded in 2005 and is headquartered in San Diego, California. Capricor Therap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people.Things to note about Capricor Therapeutics performance evaluation
Checking the ongoing alerts about Capricor Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Capricor Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Capricor Therapeutics is way too risky over 90 days horizon | |
| Capricor Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 22.27 M. Net Loss for the year was (40.47 M) with loss before overhead, payroll, taxes, and interest of (64.75 M). | |
| Capricor Therapeutics currently holds about 51.42 M in cash with (40 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11. | |
| Roughly 17.0% of the company shares are held by company insiders |
- Analyzing Capricor Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Capricor Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Capricor Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Capricor Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Capricor Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Capricor Therapeutics' stock. These opinions can provide insight into Capricor Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.